GlassScriptPhysician profile
Susan Choe
NPI 1982368700
$6,765.00
in general payments reported to CMS, 2019-2025
54 companies · $4,037 in 2025
The $4,037 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $325 · 2024: $2,403 · 2025: $4,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,364 · Education: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,363.52 |
| Education | $1,401.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $512.12 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Astellas Pharma US INC | $417.66 | 2024-2025 | Xospata |
| Sobi, INC | $415.27 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $400.95 | 2024-2025 | |
| Gilead Sciences, INC. | $399.66 | 2024-2025 | Trodelvy |
| Janssen Biotech, INC. | $342.35 | 2024-2025 | Talvey, Tecvayli, Erleada |
| Incyte Corporation | $316.87 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $308.18 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Lilly USA, LLC | $291.88 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $242.31 | 2023-2025 | Enhertu, Lynparza, Imfinzi |
| Abbvie INC. | $230.97 | 2024-2025 | |
| Daiichi Sankyo INC. | $205.79 | 2023-2025 | Enhertu |
| Eisai INC. | $200.52 | 2023-2025 | |
| Array Biopharma INC | $189.13 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Puma Biotechnology, INC. | $152.68 | 2024-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.66 | 2024-2025 | Gilotrif |
| Emd Serono, INC. | $129.03 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.51 | 2023-2025 | |
| Pfizer INC. | $122.24 | 2024-2025 | |
| Exelixis INC. | $109.37 | 2024-2025 | Cabometyx |
| Stemline Therapeutics INC. | $99.90 | 2025 | Orserdu |
| Seagen INC. | $95.00 | 2025 | |
| Genzyme Corporation | $90.00 | 2024-2025 | |
| Beigene USA, INC. | $83.79 | 2024-2025 | Brukinsa |
| Blueprint Medicines Corporation | $82.35 | 2024-2025 | Ayvakit |
| Celgene Corporation | $80.89 | 2024-2025 | Reblozyl, Opdivo |
| Karyopharm Therapeutics INC. | $74.62 | 2024-2025 | Xpovio |
| Genentech USA, INC. | $64.72 | 2025 | Polivy, Phesgo |
| Genmab U.S., INC. | $63.49 | 2024-2025 | Epkinly |
| Pharmacosmos Therapeutics INC. | $53.95 | 2025 | Monoferric |
| Novocure INC. | $48.19 | 2025 | Optune Lua (Novottf-200t) |
| Immunogen, INC. | $45.53 | 2023-2024 | Elahere, Elahere |
| Rigel Pharmaceuticals, INC. | $45.37 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Coherus Oncology, INC. | $42.34 | 2024-2025 | Loqtorzi |
| Deciphera Pharmaceuticals INC. | $40.07 | 2024-2025 | Tgct, Qinlock |
| Mirati Therapeutics, INC. | $38.49 | 2023 | Krazati |
| Glaxosmithkline, LLC. | $35.32 | 2024-2025 | Ojjaara |
| Novo Nordisk INC | $34.01 | 2023 | Rybelsus, Ozempic |
| Tersera Therapeutics LLC | $32.21 | 2025 | Zoladex |
| E.R. Squibb & Sons, L.L.C. | $30.99 | 2025 | |
| Pharmaessentia USA Corporation | $30.76 | 2024 | Besremi |
| Taiho Oncology, INC. | $29.48 | 2024 | |
| Recordati_rare_diseases_inc. | $29.43 | 2025 | Enjaymo |
| Octapharma USA, INC. | $28.43 | 2025 | Octagam Immune Globulin (Human) |
| Agios Pharmaceuticals, INC. | $26.69 | 2025 | Pyrukynd |
| Immunocore Limited | $25.84 | 2025 | Kimmtrak |
| Tolmar, INC. | $25.14 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $24.62 | 2025 | Somatuline Depot, Onivyde |
| Shockwave Medical, INC | $23.48 | 2025 | |
| Accord Healthcare, INC. | $22.60 | 2023 | |
| Legend Biotech USA INC. | $20.82 | 2025 | Carvykti |
| Verity Pharmaceuticals INC. | $17.23 | 2025 | Trelstar |
| Servier Pharmaceuticals LLC | $16.42 | 2025 | |
| Shorla Oncology INC. | $14.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Choe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.